Novo Nordisk Operating Income Over Time
| NVO Stock | USD 47.19 3.11 6.18% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Novo Nordisk Performance and Novo Nordisk Correlation. Will Pharmaceuticals sector continue expanding? Could Novo diversify its offerings? Factors like these will boost the valuation of Novo Nordisk. Anticipated expansion of Novo directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Novo Nordisk data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.27) | Dividend Share 11.65 | Earnings Share 3.64 | Revenue Per Share | Quarterly Revenue Growth 0.051 |
Understanding Novo Nordisk AS requires distinguishing between market price and book value, where the latter reflects Novo's accounting equity. The concept of intrinsic value - what Novo Nordisk's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Novo Nordisk's price substantially above or below its fundamental value.
It's important to distinguish between Novo Nordisk's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Novo Nordisk should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Novo Nordisk's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Novo Nordisk AS and related stocks such as Merck Company, Novartis AG ADR, and Abbott Laboratories Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRK | 839.8 M | 9 B | 9.9 B | 7.7 B | 6.7 B | 7.5 B | 5.5 B | 6.8 B | 8.9 B | 7.9 B | 5.5 B | 13.2 B | 18.3 B | 3 B | 20.2 B | 26.8 B | 28.1 B |
| NVS | 5 B | 10.8 B | 11.5 B | 11 B | 11.1 B | 9 B | 8.3 B | 8.7 B | 8.4 B | 9.1 B | 10.2 B | 10.1 B | 7.9 B | 9.8 B | 14.5 B | 16.7 B | 9.3 B |
| ABT | 737.1 M | 6.8 B | 2 B | 2.1 B | 2.9 B | 2.9 B | 3.2 B | 2 B | 3.8 B | 4.6 B | 5.3 B | 9.2 B | 8.4 B | 6.4 B | 6.8 B | 8 B | 4.1 B |
| AZN | 1.2 B | 12.8 B | 8.1 B | 3.7 B | 2.1 B | 4.1 B | 4.9 B | 3.7 B | 3.4 B | 2.9 B | 5.2 B | 1.1 B | 3.8 B | 8.2 B | 10 B | 11.5 B | 12.1 B |
| GILD | (4.8 M) | 3.8 B | 4 B | 4.5 B | 15.3 B | 22.2 B | 17.6 B | 14.1 B | 8.2 B | 4.3 B | 4.1 B | 9.9 B | 7.3 B | 7.6 B | 1.7 B | 1.9 B | 1.8 B |
| PFE | 880 M | 18.4 B | 18 B | 16.9 B | 14 B | 13.3 B | 14.3 B | 14.4 B | 15.3 B | 7.5 B | 9.1 B | 20.8 B | 37.5 B | 5.3 B | 16.5 B | 15.4 B | 11.2 B |
| TMO | 4.9 M | 1.5 B | 1.6 B | 1.8 B | 2.3 B | 2.5 B | 2.9 B | 3.3 B | 3.9 B | 4.3 B | 7.9 B | 10.3 B | 8.5 B | 6.9 B | 7.7 B | 8.1 B | 8.5 B |
| AMGN | (900 K) | 4.3 B | 5.6 B | 5.9 B | 6.2 B | 8.5 B | 9.8 B | 10 B | 10.3 B | 9.7 B | 9.1 B | 7.6 B | 9.6 B | 7.9 B | 7.3 B | 14.9 B | 15.6 B |
| SNY | 971 M | 5.9 B | 6.4 B | 5 B | 6.1 B | 5.6 B | 6.5 B | 5.8 B | 4.7 B | 3.1 B | 14.1 B | 8.1 B | 10.2 B | 7 B | 7.3 B | 6.3 B | 6.1 B |
| GSK | 619 M | 7.8 B | 7.3 B | 7 B | 3.6 B | 10.3 B | 2.6 B | 4.1 B | 5.5 B | 7 B | 6 B | 4.4 B | 6.4 B | 6.7 B | 4 B | 4.6 B | 4.7 B |
Novo Nordisk AS and related stocks such as Merck Company, Novartis AG ADR, and Abbott Laboratories Operating Income description
Operating Income is the amount of profit realized from Novo Nordisk AS operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Novo Nordisk AS is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Novo Nordisk AS | NVO |
| Classification | Giant Impact |
| Business Address | Novo Alle 1, |
| Exchange | New York Stock Exchange |
USD 47.19
Check out Novo Nordisk Performance and Novo Nordisk Correlation. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Novo Nordisk technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.